Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Dr. Overman Discusses ReDOS Study in mCRC

February 26th 2019

Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the ReDOS study in patients with metastatic colorectal cancer.

Molecular Testing Needed to Inform CRC Treatment Decisions

February 25th 2019

Michael Overman, MD, highlights data from pivotal trials presented at the 2019 Gastrointestinal Cancers Symposium and discusses where research efforts should be focused to improve the treatment of patients with colorectal cancer.

Dr. Eng on Recognizing Tumor Sidedness in mCRC

February 23rd 2019

Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses recognizing tumor sidedness in the treatment of patients with metastatic colorectal cancer.

Eng Highlights Important Treatment Considerations in mCRC

February 22nd 2019

Cathy Eng, MD, FACP, discusses the current treatment options available for patients with metastatic colorectal cancer and highlights recent data in the space.

Dr. Lee on the Benefit of Cytoreductive Surgery in Metastatic Colorectal Cancer

February 21st 2019

Byrne Lee, MD, chief, Upper GI and Mixed Tumor Surgery Service, associate professor of surgical oncology, City of Hope, discusses the benefit of cytoreductive surgery in the treatment of patients with metastatic colorectal cancer (mCRC).

Dr. Nelson on Novel Combination Therapies in Colorectal Cancer

February 19th 2019

Douglas A. Nelson, MD, Department of General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses novel combination therapies in colorectal cancer (CRC).

Dr. Mizrahi on Bevacizumab as a Chemoprotectant in CRC

February 15th 2019

Jonathan Mizrahi, MD, hematology/oncology fellow, The University of Texas MD Anderson Cancer Center, discusses bevacizumab (Avastin) as a chemoprotectant in colorectal cancer (CRC).

Dr. Kasi on Role of Immunotherapy in mCRC

February 14th 2019

Pashtoon M. Kasi, MD, MBBS, MS, assistant professor of oncology and senior associate consultant in the Division of Hematology/Oncology at Mayo Clinic, discusses the role of immunotherapy in the treatment of patients with metastatic colorectal cancer.

Improving Care for Patients With Colon/Rectal Cancer

February 14th 2019

Neoadjuvant Strategies for Rectal Cancer

February 14th 2019

Adjuvant Therapy for High-Risk Colon Cancer

February 14th 2019

Patient Stratification in Colon Cancer: ctDNA

February 14th 2019

Adjuvant Therapy for Early-Stage Colon Cancer

February 14th 2019

Relapsed/Refractory mCRC: Treatment Dosing Strategies

February 14th 2019

Treatment Recommendations for Relapsed/Refractory mCRC

February 14th 2019

Rationale for I-O in mCRC

February 14th 2019

Management of NTRK Fusions in CRC

February 14th 2019

Triplet Regimens for BRAF V600E-Positive mCRC

February 14th 2019

Sequencing Therapy in CRC: REVERCE Trial

February 14th 2019

Sequencing Therapy in CRC: E7208 Trial

February 14th 2019